Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
Wei-Ying JenKoiji SasakiSanam LoghaviSa A WangWei QiaoGautam BorthakurFarhad RavandiTapan Mahendra KadiaGhayas C IssaNicholas James ShortMusa YlimazNaval G DaverCourtney D D DiNardoPublished in: British journal of haematology (2024)
Targeted therapy development for acute myeloid leukaemia (AML) requires an understanding of specific expression profiles. We collected flow cytometry data on 901 AML patients and recorded aberrant CD7 expression on leukaemic blasts. 263 (29.2%) had blasts positive for CD7. CD7+ AML was more likely to be adverse risk (64.6% vs. 55.6%, p = 0.0074) and less likely to be favourable risk (15.2% vs. 24.1%, p = 0.0074) by European LeukemiaNet 2022 criteria. Overall survival was inferior (11.9 [95% CI, 9.7-15.9] vs. 19.0 months [95% CI, 16.1-23.0], p = 0.0174). At relapse, 30.4% lost and 19.0% gained CD7, suggesting moderate instability over time.
Keyphrases
- acute myeloid leukemia
- flow cytometry
- poor prognosis
- liver failure
- end stage renal disease
- respiratory failure
- dendritic cells
- ejection fraction
- allogeneic hematopoietic stem cell transplantation
- bone marrow
- newly diagnosed
- drug induced
- chronic kidney disease
- nk cells
- aortic dissection
- binding protein
- high intensity
- long non coding rna
- big data
- emergency department
- hepatitis b virus
- metabolic syndrome
- adipose tissue
- skeletal muscle
- mechanical ventilation
- patient reported
- breast cancer risk